Company Filing History:
Years Active: 2018
Title: Prakash Radhakrishnan: Innovator in Cancer Treatment
Introduction
Prakash Radhakrishnan is a notable inventor based in Omaha, NE (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on utilizing monoclonal antibodies to target specific glycoproteins, which can inhibit tumor growth.
Latest Patents
Radhakrishnan holds a patent for a method of targeting glycoproteins to treat cancer. The patent, titled "Method of targeting glycoproteins to treat cancer," describes a technique for inhibiting tumor growth. Specifically, it involves the use of monoclonal antibodies to target truncated O-glycans on glycoproteins, thereby inhibiting the activation of pro-survival cell signaling pathways. For instance, monoclonal antibody AR9.6 can be employed to target truncated O-glycans on the MUC16 glycoprotein, which inhibits the phosphatidylinositol 3-kinase/Akt (Pi3K/Akt) signaling pathway. Radhakrishnan has 1 patent to his name.
Career Highlights
Radhakrishnan is affiliated with the University of Nebraska, where he conducts his research. His work has garnered attention for its potential impact on cancer therapies and treatment methodologies. He is dedicated to advancing the understanding of glycoproteins in cancer biology.
Collaborations
Radhakrishnan collaborates with Michael Anthony Hollingsworth, who is also involved in cancer research. Their partnership enhances the research efforts at the University of Nebraska, contributing to innovative solutions in the fight against cancer.
Conclusion
Prakash Radhakrishnan is a pioneering inventor whose work in targeting glycoproteins represents a significant advancement in cancer treatment. His contributions to the field are invaluable and hold promise for future therapeutic developments.